|
Sub-category:
Lymphoma, Adult
Category:
leukemia/Lymphoma (Adult)
Meeting:
2002 ASCO Annual Meeting
Abstract No:
1061
Citation:
Proc Am Soc Clin Oncol 21: 2002 (abstr 1061)
Author(s):
Leo I Gordon, Thomas E Witzig, Christos E Emmanouilides, Andrew Raubitschek, Stewart Spies, Greg Wiseman, Richard Ugoretz, Christine A White, Northwestern University Medcl School, Chicago, IL; Mayo Clinic, Rochester, MN; University of California Los Angeles, Los Angeles, CA; City of Hope Natl Medcl Ctr, Duarte, CA; University of Alabama, Birmingham, AL; IDEC Pharmaceuticals Corp, San Diego, CA.
Abstract:
Zevalin is composed of the murine antiùCD20 monoclonal antibody, ibritumomab, covalently bound to tiuxetan which stably chelates the beta emitting radionuclide, yttriumù[90]. In clinical trials 90Y ibritumomab tiuxetan has produced meaningful responses in patients with advanced, Bùcell nonùHodgkin¦s lymphoma (NHL). In a Phase I/II dose finding clinical trial, 51 patients with relapsed or refractory Bùcell NHL were treated with the 90Y ibritumomab tiuxetan regimen (preinfusion with rituximab 250 mg/m2 to clear peripheral Bùcells and improve biodistribution followed by 111In ibritumomab tiuxetan 5 mCi on day 1 for imaging and 90Y ibritumomab tiuxetan 0.3 ù 0.4 mCi/kg on day 8). Patients were required to have ANC >1,500/mm3, platelets >100,000/mm3 and bone marrow involvement <25%. Twelve patients with diffuse mixed (3) and diffuse large cell (9) histology were included in this trial. Median age was 58 years. Patients had a median of 2 prior regimens (range 1 ù 4) including ESHAP, DHAP, ICE and other regimens. All had prior CHOP or CHOPùlike regimens. Overall response rate was 58% in these patients (International Workshop NHL Response Criteria). Thirty three percent achieved a complete response. Median duration of response has not been reached at 35.5 months followùup (range 2.4 ù 40+ months). Median time to next antiùcancer treatment for all patients was 9.9 months. Toxicity was primarily hematologic. Grade 4 neutropenia occurred in 17%, thrombocytopenia in 8%. All patients recovered from hematologic toxicity. Nonùhematologic toxicity was Grade 1 or 2. In this small population of heavily preùtreated NHL patients, aggressive histology did not preclude meaningful responses to 90Y ibritumomab tiuxetan radioimmunotherapy with acceptable toxicity. Further studies with Zevalin in diffuse aggressive lymphomas are warranted.
 Associated Presentation(s):
Other Abstracts in this Sub-Category:
Abstracts by Leo I Gordon:
Presentations by Leo I Gordon:
Educational Book Manuscripts by Leo I Gordon:
|
